Professional Documents
Culture Documents
Emergency Medicine EducationGuillain-Barré Syndrome - Third Time's The Charm - EmDOCs - Net - Emergency Medicine Education
Emergency Medicine EducationGuillain-Barré Syndrome - Third Time's The Charm - EmDOCs - Net - Emergency Medicine Education
NET/EM3AM-ASYMPTOMATIC-HYPERTENSION/)
NEXT POST (HTTP://WWW.EMDOCS.NET/MINDSET-MEDICAL-EDUCATION-MINDSET-PLAY-
ROLE-SUPPORT-MEDICAL-MISTAKE-ADVERSE-EVENT/)
Case: 60 year-old male PMH of Htn, DM, presents to the ED with complaints of generalized
weakness and fatigue. His family states you are the third provider he has seen in the last week.
He was seen by the primary care doctor for fever and cough 5 days prior and started on
Azithromycin for bronchitis and was seen at the Urgent care for fatigue and weakness 1 day
prior to presentation where he was treated with IVF. Despite antibiotics and IVF, he reports
continued symptoms of generalized weakness. He denies focal weakness, headache or neck
stiffness and has an otherwise negative ROS. Vital signs are within normal limits on arrival. PE
reveals a normal exam except for the neurologic component which identi es decreased strength
in bilateral LE with are exia. What is your next step?
Background:
How common is GBS?
Guillain-Barré Syndrome (GBS) has an estimated incidence of 1 to 4 per 100,0001 making it the
most common cause of acute generalize paralysis since the virtual elimination of
poliomyelitis2,3. GBS is a commonly missed diagnosis in the ED which has the potential to
progress to signi cant morbidity1.
De nition
Guillain-Barré Syndrome is an in ammatory peripheral neuropathy. Up to 88% of patients
affected by GBS have a prodromal infection4. As an aberrant response to a precipitating
infection, a primarily lymphocytic T cell mediated and macrophage mediated response results in
demyelination, although the exact mechanism is still under investigation2. It is however become
clearer that infection can induce antibodies that then cross react with neural antigens which
leads to the resultant in ammatory neuropathy5.
It can present with paresthesia, ascending weakness, and are exia one to six weeks after
infectious prodrome4, although there are variable presentations within the 4 subtypes as seen in
the box below. Miller-Fischer syndrome accounts for 5% of the cases and includes ataxia and
ophthalmoplegia in addition to the are exia1.
From: https://www.uspharmacist.com/article/guillain-barre-syndrome
The most common infections are from cytomegalovirus and Campylobacter jejuni1,2. There are
4 main phases of the disease process including:
lb h i ii i f i ill d h f l
1. Interval between the inciting infection illness and the onset of neuromuscular symptoms
2. Progressive weakness lasting less than one month
3. Plateau/nadir
4. Recovery
The onset of symptoms may vary although there is a rapidly progressive form that can result in
quadriplegia and respiratory failure within 48 hours1 and is associated with poorer outcomes5.
From: https://www.ahcmedia.com/articles/12128-key-neuromuscular-junction-disorders-
and-peripheral-neuropathies-for-the-emergency-physician
Onset of symptoms of weakness within the last 24 hours should raise concerns for GBS,
Myasthenia gravis, tick paralysis, stroke, or acute porphyric neuropathy6.
The chief complaint may center on complaints of pain or paresthesia/weakness3. The course
can begin with ne paresthesia in the toes or ngertips that is followed within days by leg
weakness2. Initially, the weakness may be proximal, distal, or both5 and typically ascends from
the lower extremities upward symmetrically. Patients will often complain of weakness that
makes it dif cult to walk or climb stairs. Pain is a common complaint, described as aching in the
large muscle of the upper legs, anks or back or as bilateral sciatica pain2.
From: http://www.natural-health-news.com/guillain-barre-syndrome-causes-symptoms-
diagnoses-and-treatment/
Diagnostic Considerations:
Nerve conduction abnormalities occur earlier and more frequently than the elevation of protein
in cerebrospinal uid due to the re ecting demyelination and thus electrophysiology studies
such as electromyography (EMG) are the most sensitive and speci c diagnostic tool2 . However,
this is usually not feasible to attain in the ED1 raising use of a thorough history, physical exam,
and lumbar puncture as the tools to help a clinician correctly make this diagnosis.
From: https://www.slideshare.net/drpramodkrishnan/gb-syndrome
Intubation/RSI pearls
Weakness of the respiratory muscles can cause patients with GBS to require arti cial ventilation
in up to 25% of patients1,5. Regular monitor of vital capacity can be useful in determining if
prophylactic intubation is necessary5. Early intubation is recommended for patients for airway
protection with guidance using the 20-30-40 rule (given in the following box)6. Other potential
indications would be inability to lift head or shoulders, inability cough, rapid onset of symptoms6.
Medication Considerations
14
Plasma exchange versus immunoglobulin (IVIG) therapy are the mainstay therapy1,4 and are
more ef cacious when started during the rst 2 weeks of symptoms6. However since continued
research including randomized controlled trials have showed similar ef cacy to plasma
exchange, IVIG has replaced plasma exchange in treatment of severe GBS due to convenience5.
CSF analysis should be done before initiating IVIG as the implementation of IVIG may cause an
aseptic meningitis5. The American Academy of Neurology practice parameter does recommend
either plasma exchange or IVIG for treatment of GBS patients who have lost the ability to walk,
although best practice is still undecided5. Corticosteroids are no longer considered useful in the
therapy for GBS2.
From: http://www.nature.com/nrneurol/journal/v10/n8/full/nrneurol.2014.121.html
Disposition
Hospitalization for observation for at least several days should occur for almost all patients with
Guillain-Barré Syndrome2. Mild cases that include only mildly distal paresthesia or mild limb
weakness may not warrant therapy, although it is suggested to wait approximately two weeks
before concluding that there will be no further progression2. Intensive Care admission should
be considered in patient with cardiovascular dysautonomia or those patient with a vital capacity
that is <18ml/kg body weight or is rapidly declining2.
Prognosis
Weakness typically stops advancing in one to four weeks, with a nadir by 2 weeks, eventually
reaching a plateau phase by 4 weeks in nearly all cases2,5. A typical patient during this process
will become bedridden due to the weakness with distal paresthesia, incomplete bilateral
weakness of facial muscles, dif culty swallowing and half of the predicted vital capacity2. There
are varying degrees of the severity and identi cation of this is crucial to ensure the best
outcomes. In both adult and children, the severity of the disease at the nadir has been identi ed
as an adverse prognostic factor (expressed as being bed bound or requiring arti cial
ventilation)5.
Prompt treatment has been associated with good long-term outcomes including an 85% full
recovery6. Between 4-15% of patients die despite medical therapy, from largely avoidable
complications such as sepsis, adult respiratory distress syndrome, pulmonary embolism, and
dysautonomia leading to cardiac arrest2 with some references stating up to 20% being
permanently disabled5. Minor residual de cits can be seen in up to 65 percent such as distal
numbness or foot drop although this does not impair daily life2. Disabling weakness, imbalance
or sensory loss occur in 5 to 10 percent2. Poorer outcomes are seen in patients who had rapid
onset of symptoms5. Patients who at the nadir of 2 weeks are still able to walk, are likely to
improve with or without treatment with no residual de cit5. Multi-disciplinary rehabilitation is
essential in the recovery of GBS patients.
The illness tends to be less severe in children than adult2 with recovery being more rapid and
complete5. Also, if this occurs during pregnancy, it typically occurs during the third trimester or
post-partum and does not affect the fetus suggesting that the maternal IgG does not cause nerve
in ammation or demyelination2.
Case Resolution
The patient was admitted to neurology step down and had progression of his disease resulting in
intubation the next morning due to respiratory depression. IVIG was started in the intensive
care unit and the patient’s symptoms stabilized. He was eventually extubated and transferred to
the oor. He was transitioned to a rehabilitation facility to help with physical therapy and
strength training.
References/Further Reading
1. Noto, A., & Marcolini, E. (2014). Select Topics in Neurocritical Care. Emergency Medicine Clinics of
North America, 32(4), 927-938.
2. Ropper A.H.: The Guillain-Barre syndrome. N Engl J Med 1992; 326: pp1130-1136.
3. McGillicuddy D.C., Walker O., Shapiro N.I., et al: Guillain-Barre syndrome in the emergency department.
Ann Emerg Med 2006; 47: 390-393.
4. Sheridan, J. (2010). Atypical Guillain-Barre in the emergency department. West J of Emerg Med, 11(1),
80-82.
5. Ganti, L., & Rastogi, V. (2016). Acute Generalized Weakness. Emergency Medicine Clinics of North
America, 34(4), 794-809.
6. Hughes RAC, Cornblath DR. Guillain-Barre Syndrome. Lancet 2005; 366: 1653-66.
7. Roppolo L.P., and Walters K.: Airway management in neurological emergencies. Neurocrit Care 2004; 1:
405-414.
Share this:
Email (http://www.emdocs.net/guillain-barre-syndrome-third-times-charm/?share=email&nb=1)
Print (http://www.emdocs.net/guillain-barre-syndrome-third-times-charm/#print)
Pingback: Guillain-Barré Syndrome – Third time’s the charm – Verpleegkundig specialisten SEH
(https://vsseh.wordpress.com/2017/05/24/guillain-barre-syndrome-third-times-the-charm/)
LEAVE A REPLY
Your email address will not be published. Required elds are marked *
Comment
Name *
Email *
Website
Save my name, email, and website in this browser for the next time I comment.
Post Comment
(https://ddxof.com/app)
(http://www.emdocs.net/wp-content/uploads/2019/10/transfusion_lg.png)
(https://www.foambase.org/search.php?search=cme)
Next »
More Than a Hot Shower – Treatment for Cannabinoid Hyperemesis Syndrome (CHS)
(http://www.emdocs.net/more-than-a-hot-shower-treatment-for-cannabinoid-hyperemesis-syndrome-chs/)
(https://twitter.com/@emdocsdotnet) (https://www.facebook.com/emdocsdotnet)
(https://plus.google.com/+emdocsnet)
FEATURED ARTICLES
(http://www.emdocs.net/more-than-a-hot-shower- (http://www.emdocs.net/journal-feed-weekly-wrap-
treatment-for-cannabinoid-hyperemesis-syndrome- up-25/)
chs/) In the Literature
practice updates
This blog aims to disrupt how medical providers and trainees can gain public access to high-quality, educational
content while also engaging in a dialogue about best-practices in EM and medical education. We strive to reshape
medical education and academia in their evolution beyond the traditional classroom.
RECENT
All Content (http://www.emdocs.net/collected- Ask Me Anything
knowledge/) (http://www.emdocs.net/category/ama/)
EM Mindset (http://www.emdocs.net/category/em- For Junior Residents
mindset/) (http://www.emdocs.net/category/intern-report/)
MORE Write For emDocs
(http://www.emdocs.net/about/#questions)
About (http://www.emdocs.net/about/) Contact (http://www.emdocs.net/contact/)
Search Would you like to contribute? Have feedback or
GET IN TOUCH
suggestions on how we can improve the site? Click below to contact us or nd us on Twitter, Facebook or Google+
Contact Us (http://www.emdocs.net/contact/)
(https://twitter.com/@emdocsdotnet) (https://www.facebook.com/emdocsdotnet)
(https://plus.google.com/+emdocsnet)
emDocs is licensed under a Creative Commons Attribution 4.0 International License. Powered by Gomalthemes.